Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652121 | 0.87 | POLB (0.60) | MEN1KMT2APOLBS1PR3ALDH1A1 | |
| SCHEMBL1593502 | 0.85 | ALDH1A1 (0.76) | MEN1KMT2APOLBS1PR3ALDH1A1 | |
| SCHEMBL16615791 | 0.84 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6699009 | 0.82 | POLB (0.69) | MEN1KMT2APOLBS1PR3ALDH1A1 | |
| SCHEMBL7651771 | 0.82 | ALDH1A1 (0.61) | MEN1KMT2APOLBS1PR3ALDH1A1 | |
| SCHEMBL1593930 | 0.79 | ALDH1A1 (0.67) | MEN1KMT2APOLBALDH1A1HTT | |
| SCHEMBL7657605 | 0.78 | POLB (0.51) | MEN1KMT2APOLBS1PR3ALDH1A1 | |
| SCHEMBL1383257 | 0.78 | POLB (1.00) | MEN1KMT2APOLBS1PR3SMN1; SMN2 | |
| SCHEMBL7657327 | 0.77 | POLB (0.65) | MEN1KMT2APOLBS1PR3ALDH1A1 | |
| SCHEMBL10169748 | 0.75 | CA1 (0.69) | MEN1KMT2AALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6407120-B1 | ADMINISTERING PYRIDINYLACETAMIDE OR PHENYLACETAMIDE DERIVATIVE TO TREAT CARDIOVASCULAR, EATING, SEXUAL, BRAIN, NERVOUS SYSTEM, GASTROINTESTINAL, UROGENITAL, PSYCHOLOGICAL, AND RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2002-06-18 | — | — | US | claimed |
| EP-1033366-A2 | Amide derivatives useful as Neuropeptide Y (NPY) antagonists | Pfizer Products Inc. (US) | 2000-09-06 | — | — | EP | claimed |
| US-8217001-B2 | Modification of feeding behavior | IMPERIAL INNOVATIONS LIMITED | 2012-07-10 | — | — | US | disclosed |
| US-7919329-B2 | Using proopiomelanocortin neuronal regulatory sequences to identify agents that affects caloric intake, energy expenditure, appetite or food intake; treating eating disorders and/or cachexia | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-2050460-A1 | PYY and agonists thereof for modification of feeding behaviour | Imperial Innovations Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| US-7459432-B2 | Modification of feeding behavior | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2008-12-02 | — | — | US | disclosed |
| US-20080213803-A1 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH & SCIENCE UNIVERSITY | 2008-09-04 | — | — | US | disclosed |
| CN-100350968-C | Modification of feeding behavior | IMP COLLEGE INNOVATIONS LTD (GB) | 2007-11-28 | — | — | CN | disclosed |
| EP-1585956-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | Oregon Health and Science University (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1499277-A4 | MODIFICATION OF FEEDING BEHAVIOR | IMP COLLEGE INNOVATIONS LTD (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-11 | — | — | US | disclosed |
| CN-1596119-A | Modification of feeding behavior | IMP COLLEGE INNOVATIONS LTD (GB) | 2005-03-16 | — | — | CN | disclosed |
| EP-1499277-A2 | MODIFICATION OF FEEDING BEHAVIOR | Imperial College Innovations Limited (GB) | 2005-01-26 | — | — | EP | disclosed |
| US-20050015820-A1 | Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | disclosed |
| WO-2003026591-A9 | MODIFICATION OF FEEDING BEHAVIOR | IMP COLLEGE INNOVATIONS LTD (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003026591-A2 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027637-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6407120-B1 | ADMINISTERING PYRIDINYLACETAMIDE OR PHENYLACETAMIDE DERIVATIVE TO TREAT CARDIOVASCULAR, EATING, SEXUAL, BRAIN, NERVOUS SYSTEM, GASTROINTESTINAL, UROGENITAL, PSYCHOLOGICAL, AND RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| EP-1033366-A2 | Amide derivatives useful as Neuropeptide Y (NPY) antagonists | Pfizer Products Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NPY4R, NPY2R, NPY1R | MEN1 1736/4885KMT2A 3329/4885POLB 4512/4885 |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | NPY4R, NPY5R, NPY2R | MEN1 1419/4885KMT2A 1557/4885POLB 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.